{"originalText": "，2011.3.4行结肠癌根治术，术后辅助化疗6周期，定期复查。2013-3腹部淋巴结增大，开始FOLFIRI+BEV化疗6周期。3周期、6周期，评效PR，消化道反应重，，末次化疗时间：2013.6.18，，2013-6-28复查腹盆CT：腹部多发淋巴结同前相仿。胸部CT扫描未见占位征象。改为希罗达+BEV维持治疗20周期，末次化疗时间2014-5-4。2013-8-14复查肿瘤较前继续缩小，无明显不良反应。2013.10.25复查腹盆CT示肿瘤稳定，2013-12-13行腹盆CT提示病变SD。2014-2-24复查评效为SD。2014-5-5 复查腹盆CT见肝门区肿大淋巴结，肠系膜血管旁淋巴结。XX主任医生建议继续希罗达+BEV联合治疗及拟行腹膜后局部放疗。现患者一般情况可，进食可，大便3-5次/天，体重较前无明显变化。，计划：直肠癌腹膜后淋巴结PTV54GY/27F.5-26放疗2次。", "entities": [{"end_pos": 16, "label_type": "手术", "overlap": 0, "start_pos": 10}, {"end_pos": 43, "label_type": "解剖部位", "overlap": 0, "start_pos": 38}, {"end_pos": 59, "label_type": "药物", "overlap": 0, "start_pos": 56}, {"label_type": "影像检查", "overlap": 0, "start_pos": 115, "end_pos": 119}, {"label_type": "解剖部位", "overlap": 0, "start_pos": 120, "end_pos": 121}, {"label_type": "影像检查", "overlap": 0, "start_pos": 132, "end_pos": 136}, {"end_pos": 150, "label_type": "药物", "overlap": 0, "start_pos": 147}, {"end_pos": 154, "label_type": "药物", "overlap": 0, "start_pos": 151}, {"label_type": "影像检查", "overlap": 0, "start_pos": 218, "end_pos": 222}, {"label_type": "影像检查", "overlap": 0, "start_pos": 239, "end_pos": 243}, {"label_type": "影像检查", "overlap": 0, "start_pos": 278, "end_pos": 282}, {"end_pos": 285, "label_type": "解剖部位", "overlap": 0, "start_pos": 283}, {"end_pos": 301, "label_type": "解剖部位", "overlap": 0, "start_pos": 292}, {"end_pos": 315, "label_type": "药物", "overlap": 0, "start_pos": 312}, {"end_pos": 319, "label_type": "药物", "overlap": 0, "start_pos": 316}, {"label_type": "解剖部位", "overlap": 0, "start_pos": 326, "end_pos": 327}, {"label_type": "疾病和诊断", "overlap": 0, "start_pos": 370, "end_pos": 373}, {"end_pos": 379, "label_type": "解剖部位", "overlap": 0, "start_pos": 373}]}
